All In Biotech

Drug Trial Radar · NCT04124965

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

71

Actual

Start

Oct 29, 2019

Primary completion

Sep 1, 2021

Study completion Sep 1, 2021

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline until End of Study (up to Week 60)
  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of Study MedicationTime frame: From Baseline until End of Study (up to Week 60)

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • Mg0004 50081

    Phoenix, Arizona

  • Mg0004 50072

    Los Angeles, California

  • Mg0004 50088

    Washington D.C., District of Columbia

  • Mg0004 50120

    Miami, Florida

  • Mg0004 50073

    Tampa, Florida

  • Mg0004 50114

    Indianapolis, Indiana

  • Mg0004 50121

    Lexington, Kentucky

  • Mg0004 50077

    New York, New York

  • Mg0004 50090

    Winston-Salem, North Carolina

  • Mg0004 50096

    Philadelphia, Pennsylvania

  • Mg0004 50066

    Montreal, Canada

  • Mg0004 50070

    Québec, Canada

  • Mg0004 50069

    Toronto, Canada

  • Mg0004 40125

    Ostrava-Poruba, Czechia

  • Mg0004 40124

    Prague, Czechia

  • Mg0004 40128

    Aalborg, Denmark

  • Mg0004 40129

    Bordeaux, France

  • Mg0004 40132

    Nice, France

  • Mg0004 40133

    Paris, France

  • Mg0004 40131

    Strasbourg, France

  • Mg0004 40140

    Göttingen, Germany

  • Mg0004 40078

    Leipzig, Germany

  • Mg0004 40177

    Münster, Germany

  • Mg0004 40144

    Milan, Italy

  • Mg0004 40146

    Pavia, Italy

  • Mg0004 40148

    Roma, Italy

  • Mg0004 40150

    Roma, Italy

  • Mg0004 20078

    Hanamaki Shi, Japan

  • Mg0004 20079

    Hiroshima, Japan

  • Mg0004 20077

    Miyagi, Japan

  • Mg0004 20076

    Shinjuku-Ku, Japan

  • Mg0004 20032

    Suita, Japan

  • Mg0004 40155

    Gdansk, Poland

  • Mg0004 40154

    Lodz, Poland

  • Mg0004 40151

    Lublin, Poland

  • Mg0004 20027

    Moscow, Russia

  • Mg0004 20001

    Saint Petersburg, Russia

  • Mg0004 20028

    Saint Petersburg, Russia

  • Mg0004 20055

    Saint Petersburg, Russia

  • Mg0004 40159

    Barcelona, Spain

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.